Skip to main content
Premium Trial:

Request an Annual Quote

NCI's CPTC Issues New Call for Antibody Targets


The National Cancer Institute's Clinical Proteomic Technologies for Cancer Initiative this week issued a request for targets for monoclonal antibody production and characterization as part of its Antibody Characterization Program.

The organization will accept submissions through July 9 and will review them "based on their justification and contribution to existing NCI-funded projects," the request said. It added that "priority will be given to projects applying the antibodies to proteomics research."

The Antibody Characterization Program generates monoclonal antibodies to proteins associated with human cancer for use in the CPTC initiative. Three antibodies are generated for each protein target and characterized using assays including isotype, SDS-PAGE, Western blot, ELISA, immunohistochemistry, immuno mass spectroscopy, and surface plasmon resonance.

Antibodies and hybridoma cells are made available to researchers through the Developmental Studies Hybridoma Bank at the University of Iowa and other third-party resources.

Successful applicants will be notified on or before Aug. 30. All materials – i.e. proteins or peptides – to be used for antibody development must be ready and available at the time of the request submission.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.